Aclaris Therapts ACRS

$3.79 +0.39 (11.47%)

Valuation

Market cap
475,402,000
Revenue TTM
$7,830,000
Net income TTM
$-64,920,000
PE ratio
0.00
Forward PE
—
Profit margin
-829.12%
Debt to equity
0.00

Trading

Volume
8,735,399
Avg volume
2,810,834
Day's range
$3.18 – $3.82
Shares out
139,824,000
Stochastic %K
27%
Beta
0.87
Analysts
Strong Sell
Price target
$10.18

Price

Company profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with n...

Show more

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
484 324 7933
Website
https://www.aclaristx.com
Address
701 Lee Road, Suite 103, Wayne, United States

Latest news

Stocktwits

Acan1219 Oct 8, 11:52 PM
$ACRS AH’s New High!💰💰💰
0 replies
topstockalerts Oct 8, 8:42 PM
$ACRS I underestimated how much demand was here.
0 replies
Acan1219 Oct 8, 8:39 PM
$ACRS 💰Price💰 🚀Volume 🚀
0 replies
Acan1219 Oct 8, 8:02 PM
$ACRS Rallied to the close! Held all its Gains!! on 8.7 Million in Volume!🚀 Let’s Gooo my Real Bull’s!!💰💰💰
1 replies
Acan1219 Oct 8, 5:02 PM
$ACRS Yet another HOD!!🚀🚀
0 replies
Acan1219 Oct 8, 4:55 PM
$ACRS Is that another HOD!!🚀🚀
0 replies
Acan1219 Oct 8, 4:45 PM
$ACRS Again what I said.. The whole Biotech sector was shorted by the crooks!! Look at every Biotech Stock Chart there almost identical!! And ACRS is one of the only Biotech Stock rallying back with XBI Biotech SPDR ETF Down another $3.50 today!! That says it all!! Let’s Gooooo ACRS!!🚀🚀
0 replies
Acan1219 Oct 8, 4:37 PM
$ACRS Is that another HOD!!! 💰💰
0 replies